PAPADOPOULOS STELIOS

Average Profitability
29.89%
Insider Buys Quantity
12
Insider Buys Sum
$8.92M
Insider Sells Quantity
13
Insider Sells Sum
$25.78M

Insider Activity of PAPADOPOULOS STELIOS

According to the SEC Form 4 filings, PAPADOPOULOS STELIOS, being in a position of

  1. director at Exelixis, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 11437 shares for $240,177,
    over all time since 2008-10-30, has bought 500000 shares for $1.58M, and sold 437972 shares for $10.83M.

The largest purchase of all time was on 2015-07-27 and amounted to 15000 shares of Biogen Inc. for $4.57M.

The largest sale of all time was on 2013-03-11 and amounted to 81675 shares of Biogen Inc. for $14.07M.

Biography of PAPADOPOULOS STELIOS

No biography is available at this moment.

2024-05-20SaleExelixis, Inc.
EXEL
director
11,437
0.0039%
$21.00$240,177+22.54%
2022-02-22SaleExelixis, Inc.
EXEL
director
84,515
0.0264%
$19.56$1.65M-8.62%
2021-05-11SaleExelixis, Inc.
EXEL
director
20,770
0.0067%
$24.98$518,794-20.62%
2020-05-08SaleExelixis, Inc.
EXEL
director
45,000
0.0145%
$25.84$1.16M-12.27%
2019-05-07PurchaseRegulus Therapeutics Inc.
RGLS
director
370,370
1.9953%
$1.08$400,000-40%
2019-02-21SaleExelixis, Inc.
EXEL
director
26,250
0.0087%
$21.25$557,813-6.83%
2018-12-28PurchaseRegulus Therapeutics Inc.
RGLS
director
50,000
0.569%
$1.09$54,570-12.73%
2018-12-27PurchaseRegulus Therapeutics Inc.
RGLS
director
26,401
0.2916%
$1.04$27,460-10.65%
2018-12-26PurchaseRegulus Therapeutics Inc.
RGLS
director
90,000
0.9471%
$0.95$85,878-6.73%
2018-11-16PurchaseRegulus Therapeutics Inc.
RGLS
director
300,000
3.3093%
$1.38$415,470-27.78%
2018-11-15PurchaseRegulus Therapeutics Inc.
RGLS
director
200,000
2.3033%
$1.33$265,080-21.21%
2018-05-07SaleExelixis, Inc.
EXEL
director
15,000
0.005%
$22.15$332,250-7.11%
2018-03-02SaleExelixis, Inc.
EXEL
director
15,000
0.0051%
$24.05$360,750-14.02%
2017-09-22SaleExelixis, Inc.
EXEL
director
10,000
0.0035%
$25.40$254,000-7.19%
2017-09-19SaleExelixis, Inc.
EXEL
director
127,790
0.043%
$27.63$3.53M-16.35%
2017-09-18SaleExelixis, Inc.
EXEL
director
72,210
0.0247%
$27.76$2M-14.88%
2017-07-25PurchaseRegulus Therapeutics Inc.
RGLS
director
1M
0.9102%
$0.91$910,000-17.12%
2017-03-22PurchaseRegulus Therapeutics Inc.
RGLS
director
300,000
0.5557%
$1.23$368,100-8.8%
2017-03-21PurchaseRegulus Therapeutics Inc.
RGLS
director
200,000
0.3771%
$1.20$239,800-4.17%
2017-03-20SaleExelixis, Inc.
EXEL
director
10,000
0.0034%
$21.66$216,600+18.19%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.